The study aimed to examine the effects of the antirheumatic drug tofacitinib on metabolic syndrome associated with Rheumatoid Arthritis (RA) in a rodent model. 50 male ZSF1 rats were divided into eight groups, four lean and four obese, and treated with combinations of Complete Freund’s Adjuvant (CFA) and tofacitinib. Inflammation severity, glucose homeostasis, blood pressure, and body weight were measured, and FDG-PET scans were used to assess metabolic activity. Obese rats had worse OGTT results, higher HgbA1C levels, blood pressure, and body weight than lean ones. Tofacitinib treatment resulted in significant differences, including a decrease in the thermo-mechanical nociceptive threshold. The study suggests that tofacitinib may alleviate metabolic syndrome’s consequences, such as insulin resistance, without affecting blood pressure.